Calviri is a biotechnology company that is developing peptide array platforms. The mission of Calviri is to deliver affordable products globally, to end deaths from cancer by combining a highly immunogenic source of neoantigens with a peptide array platform. In eradicating cancer, the company will develop new diagnostic and therapeutic products, and preventative vaccines that will prevent cancer from starting.
Calviri’s approach is capable of providing cancer diagnostics and vaccines, based on the discovery of unrecognized source of frameshift neoantigens. Calviri is taking advantage of the supply of immunogenic neoantigens to create useful vaccines and diagnostics against all cancers.
Calviri is conducting the world’s largest canine cancer vaccine study to test the efficacy of a preventative vaccine against cancer, the company is using a $6.4 M grant from Open Philanthropy Project to fund the vaccine study in dogs through the ASU Foundation and in collaboration with Colorado State University .